Profluent and Lilly teamed up on AI‑designed enzymes in a deal worth up to $2.25B. Big tech, bigger gene edits.

Scientists shared transcripts with The Times in which chatbots described how to assemble deadly pathogens and unleash them in ...

Frontier AI firm Profluent has entered a multi-program strategic research collaboration with Eli Lilly and Co. LLY to develop and commercialize custom site-specific recombinases to treat genetic ...

There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...

Christine Dawood waited months for her dead loved ones' remains to be returned following the catastrophic implosion.

Profluent, which will design recombinases for the collaboration, could receive up to $2.25 billion in the deal.

Serif Biomedicines has emerged from stealth mode to continue developing “modified DNA,” a new class of therapeutics designed ...

Scientists have uncovered an unexpected way cells can generate cancer-driving proteins—by cutting RNA into shorter, functional fragments rather than following the standard blueprint. This process, ...

Mumbai real estate update: House of Hiranandani said the residential project will span across 7.6 lakh sq ft of saleable ...

Recent advances in genomics, genome editing, and imaging technologies have revealed that neural activity can rapidly alter chromatin accessibility, ...